Longitudinal Description and Prediction of Smoking Among Borderline Patients: An 18 Year Follow-Up Study

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
PHYSICIANS POSTGRADUATE PRESS
Autores
FRANKENBURG, Frances R.
TEMES, Christina M.
FITZMAURICE, Garrett M.
ZANARINI, Mary C.
Citação
JOURNAL OF CLINICAL PSYCHIATRY, v.84, n.6, article ID 22m14756, 7p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: The objectives of this study were (1) to compare smoking between recovered and non-recovered patients with borderline personality disorder (BPD) over the course of 18 years and (2) to assess baseline predictors of tobacco use in patients with BPD. Methods: A total of 264 borderline patients were interviewed concerning their smoking history beginning at the 6-year follow-up wave in a longitudinal study of the course of BPD (McLean Study of Adult Development) and re -interviewed at 2-year intervals over the next 18 years. Initial data collection of the larger study happened between June 1992 and December 1995, and the DSM-III-R and the Revised Diagnostic Interview for Borderlines (DIB-R) were used as the diagnostic instruments for BPD.Results: Recovered patients had a 48% lower prevalence of smoking than non -recovered patients at 6-year follow-up (a significant difference; P=.01). Also, the rate of decline in smoking for the recovered group was 68% and was significantly faster (P= .008) than for the non-recovered group over the subsequent 18 years. Alcohol abuse or dependence (relative risk [RR]=1.22; 95% CI,1.06-1.40; P=.005), lower levels of education (RR=1.28; 95% CI,1.15-1.42; P<.001), and higher levels of the defense mechanism of denial (RR=1.08; 95% CI,1.03-1.13; P=.002) were significant predictors of smoking in borderline patients in multivariate analyses.Conclusions: Taken together, the results of this study suggest that recovery status was an important element in the prevalence of smoking among borderline patients over time. They also suggest that smoking was predicted by 3 factors: prior psychopathology, demographics, and psychological maturity.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/58279
Referências
  1. Aly HAA, 2015, WHO TECH REP SER, V994, P1
  2. Association American Lung, 2011, Trends in Tobacco Use
  3. Bader P, 2011, INT J ENV RES PUB HE, V8, P4118, DOI 10.3390/ijerph8114118
  4. Barry D, 2009, ADDICT BEHAV, V34, P51, DOI 10.1016/j.addbeh.2008.08.008
  5. Bond M, 1996, Manual for the Defense Style Questionnaire (DSO)
  6. Braveman P, 2014, PUBLIC HEALTH REP, V129, P19, DOI 10.1177/00333549141291S206
  7. Cahill K, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003440.pub4
  8. Centers for Disease Control and Prevention (US) US Department of Health and Human Services., 2006, The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General, P727
  9. de Belmont Hollingshead A, 1957, Two Factor Index of Social Position.
  10. Donald S, 2013, J PSYCHIATR RES, V47, P1673, DOI 10.1016/j.jpsychires.2013.05.011
  11. Durkin S, 2012, TOB CONTROL, V21, P127, DOI 10.1136/tobaccocontrol-2011-050345
  12. Frankenburg FR, 2006, J PERS DISORD, V20, P71, DOI 10.1521/pedi.2006.20.1.71
  13. Frankenburg FR, 2004, J CLIN PSYCHIAT, V65, P1660, DOI 10.4088/JCP.v65n1211
  14. Frankenburg FR, 2011, J PERS DISORD, V25, P421, DOI 10.1521/pedi.2011.25.4.421
  15. Frazer K, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005992.pub3
  16. Garrett BE, 2019, PREV CHRONIC DIS, V16, DOI 10.5888/pcd16.180553
  17. Goodwin RD, 2011, DRUG ALCOHOL DEPEN, V118, P127, DOI 10.1016/j.drugalcdep.2011.03.010
  18. Grant BF, 2017, JAMA PSYCHIAT, V74, P911, DOI 10.1001/jamapsychiatry.2017.2161
  19. Hasin D, 2011, ARCH GEN PSYCHIAT, V68, P1158, DOI 10.1001/archgenpsychiatry.2011.78
  20. Hopkins DP, 2010, AM J PREV MED, V38, pS275, DOI 10.1016/j.amepre.2009.10.029
  21. Jamal A, 2016, MMWR-MORBID MORTAL W, V65, P1205, DOI 10.15585/mmwr.mm6544a2
  22. Jemal A, 2008, AM J PREV MED, V34, P1, DOI 10.1016/j.amepre.2007.09.017
  23. Kaess M, 2014, PEDIATRICS, V134, P782, DOI 10.1542/peds.2013-3677
  24. Keuroghlian AS, 2013, J PSYCHIATR RES, V47, P1499, DOI 10.1016/j.jpsychires.2013.06.012
  25. Leichsenring F, 2023, JAMA-J AM MED ASSOC, V329, P670, DOI 10.1001/jama.2023.0589
  26. Lindson-Hawley N, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006936.pub3
  27. McClave AK, 2010, AM J PUBLIC HEALTH, V100, P2464, DOI 10.2105/AJPH.2009.188136
  28. Miller WR, 2013, Motivational Interviewing: Helping People Change, V3rd, pxii
  29. Niesten IJM, 2014, PERSONAL MENT HEALTH, V8, P14, DOI 10.1002/pmh.1237
  30. Peretti-Watel P, 2007, TOB CONTROL, V16, P351, DOI 10.1136/tc.2007.020362
  31. Plante DT, 2013, PSYCHIAT RES, V210, P975, DOI 10.1016/j.psychres.2013.08.004
  32. Ridolfi ME, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.19m12753
  33. Rose JE, 2004, NICOTINE TOB RES, V6, P133, DOI 10.1080/14622200310001656957
  34. Sansone Randy A, 2011, Innov Clin Neurosci, V8, P10
  35. Schlaepfer Isabel R, 2008, Curr Drug Abuse Rev, V1, P124
  36. Shiffman S, 1996, ALCOHOL HEALTH RES W, V20, P107
  37. Smith PH, 2014, TOB CONTROL, V23, DOI 10.1136/tobaccocontrol-2013-051466
  38. SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624
  39. Substance Abuse and Mental Health Services Administration, 2017, Results from the 2016 National Survey on Drug Use and Health: Detailed Tables
  40. Substance Abuse and Mental Health Services Administration, NSDUH Series H-48, HHS Publication No (SMA) 14-4863, P1
  41. Syamlal G, 2019, AM J PREV MED, V56, P548, DOI 10.1016/j.amepre.2018.10.030
  42. Temes CM, 2019, J CLIN PSYCHIAT, V80, DOI 10.4088/JCP.18m12436
  43. Temes CM, 2018, PSYCHIAT CLIN N AM, V41, P685, DOI 10.1016/j.psc.2018.07.002
  44. Tomko RL, 2014, J PERS DISORD, V28, P734, DOI 10.1521/pedi_2012_26_093
  45. Townsend TN, 2020, PREV MED, V141, DOI 10.1016/j.ypmed.2020.106226
  46. Trull TJ, 2018, BORDER PERS DIS EMOT, V5, DOI 10.1186/s40479-018-0093-9
  47. Trull TJ, 2010, J PERS DISORD, V24, P412, DOI 10.1521/pedi.2010.24.4.412
  48. US Department of Health and Human Services, 2014, A Report of the Surgeon General, P1081
  49. Weinberger AH, 2017, J CLIN PSYCHIAT, V78, pE152, DOI 10.4088/JCP.15m10062
  50. Weinberger AH, 2015, ALCOHOL CLIN EXP RES, V39, P1989, DOI 10.1111/acer.12840
  51. WIDIGER TA, 1991, HOSP COMMUNITY PSYCH, V42, P1015
  52. World Health Organization, 2000, Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity, DOI 10.1007/978-0-387-71799-9_454
  53. Zanarini MC, 2019, J AFFECT DISORDERS, V258, P109, DOI 10.1016/j.jad.2019.08.005
  54. Zanarini MC, 2018, J CLIN PSYCHIAT, V79, DOI 10.4088/JCP.16m11153
  55. Zanarini MC, 2015, PSYCHIAT SERV, V66, P15, DOI 10.1176/appi.ps.201400055
  56. Zanarini MC, 2015, J CLIN PSYCHOPHARM, V35, P63, DOI 10.1097/JCP.0000000000000232
  57. Zanarini MC, 2013, AM J PSYCHIAT, V170, P111, DOI 10.1176/appi.ajp.2012.12020173
  58. Zanarini MC, 2011, ADDICTION, V106, P342, DOI 10.1111/j.1360-0443.2010.03176.x
  59. Zanarini MC, 2010, AM J PSYCHIAT, V167, P663, DOI 10.1176/appi.ajp.2009.09081130
  60. Zanarini MC, 2005, J PERS DISORD, V19, P19, DOI 10.1521/pedi.19.1.19.62178
  61. Zanarini MC, 2004, J CLIN PSYCHIAT, V65, P28, DOI 10.4088/jcp.v65n0105
  62. Zanarini MC, 2003, AM J PSYCHIAT, V160, P274, DOI 10.1176/appi.ajp.160.2.274
  63. Zanarini MC, 2002, J PERS DISORD, V16, P270, DOI 10.1521/pedi.16.3.270.22538
  64. Zanarini MC, 2001, COMPR PSYCHIAT, V42, P369, DOI 10.1053/comp.2001.24556
  65. ZANARINI MC, 1987, COMPR PSYCHIAT, V28, P467, DOI 10.1016/0010-440X(87)90012-5
  66. Zanarini MC, 1998, HARVARD REV PSYCHIAT, V6, P201, DOI 10.3109/10673229809000330
  67. Zanarini MC, 1989, JPers Disord, V3, P10, DOI 10.1521/PEDI.1989.3.1.10
  68. Zanarini MC, 1992, Background Information Schedule
  69. Zanarini MC, 1994, Revised Borderline Follow-up Interview

Coleções
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/23